10 Firms End Trading Week Defying Market Bloodbath

4. Geron Corp. (GERN)

Biotechnology company Geron Corp. (GERN) saw its share price increase by 1.52 percent on Friday to end at $3.35 apiece. Investors resorted to bargain hunting following a drop in its valuation on Thursday.

Albeit booking a lower net loss in the third quarter of the year, the company reported last month that net loss in the first nine months of the year was higher at $149.2 million as compared with the $132.2 million registered year-on-year.

Geron (GERN) recently announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of its drug Rytelo for treating specific types of myelodysplastic syndromes. The European Commission will now review this recommendation, with a final decision on market authorization expected in the coming months.